Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug metoprolol may shield patients from Post-Surgery heart injury

NCT ID NCT03138603

Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether metoprolol, an FDA-approved heart medication, can reduce heart damage after surgery in people with coronary artery disease. 72 adults aged 50 and older who were not already on beta-blockers took part. The drug was given after anesthesia and during hospital recovery to see if it lowered the risk of heart-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

72 people

The number who actually took part.

Started

Dec 2016

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age \>= 50 years 2. Beta-blocker naïve \[30 days prior to surgery\] 3. Previously diagnosed coronary artery disease (CAD), or 1. History of peripheral vascular disease (PVD), or 2. Chronic kidney disease (CKD) \[eGFR ≤60ml/min\], or 3. History of positive stress test or 4. At high risk for CAD (must meet at least 2 criteria): i. Age \>= 70 years ii. Hypertension iii. Diabetes requiring oral medication or insulin iv. Current smoker or some days smoker within the past 2 years 4. Major non-cardiac, elective surgery under general anesthesia Exclusion Criteria Subjects will not be enrolled if any of the following criteria exist: 1. History of stroke, or transient ischemic attack (TIA) 2. Previously diagnosed carotid disease, i.e., either 70% unilateral or 50% bilateral carotid occlusion. 3. Heart rate \<=55bpm 4. Congestive heart failure with New York Heart Association(NYHA) Functional Classification of III-IV or left ventricular heart failure with ejection fraction ≤50% 5. Severe valvular regurgitation 6. Second or third degree atrioventricular (AV) block without pacemaker 7. Active asthma or chronic obstructive pulmonary disease (COPD) with symptoms or resolving symptoms on day of surgery 8. Anemia \[HB\<=9g/dL\] 9. Allergy to beta-blockade drugs 10. Unwilling or unable to give consent for participation 11. Undergoing any carotid endarterectomy, endovascular, endoscopic, superficial, or ambulatory procedures 12. Pregnancy or lactating women 13. Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart diseases

Contacts and locations

Locations

  • University of Chicago Medicine

    Chicago, Illinois, 60637, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.